<DOC>
	<DOCNO>NCT01701050</DOCNO>
	<brief_summary>Utilizing CellSearch® technology , ability enumerate reliably reproducibly characterize circulate tumor cell ( CTC ) tumor marker predict endocrine sensitivity ( estrogen receptor [ ER ] Bcl-2 ) resistance ( HER2 Ki67 ) demonstrate . An algorithm CTC-Endocrine Therapy Index ( CTC-ETI ) construct calculated patient use CTC enumeration marker result . The primary goal study determine CTC-ETI ER positive , HER2 negative metastatic breast cancer patient initiation new endocrine therapy identification patient progress rapidly .</brief_summary>
	<brief_title>Characterization Circulating Tumor Cells ( CTC ) From Patients With Metastatic Breast Cancer Using CTC-Endocrine Therapy Index</brief_title>
	<detailed_description>Patients estrogen receptor ( ER ) positive metastatic breast cancer ( MBC ) start first line endocrine therapy ( ET ) 30-50 % chance receive clinical benefit . For 50-70 % patient , ET ineffective patient probably treat chemotherapy , do ER negative patient . More importantly , nearly every clinical trial ET ER positive , MBC patient , 15-30 % enrol patient progress first 2-3 month , regardless whether receive first later line ET . Currently validate method identify ER positive MBC patient refractory ET . Therefore , almost ER positive patient treat serial endocrine therapy switch chemotherapy . The investigator propose subset patient would well serve chemotherapy , spite increase toxicity profile , rather delay chemotherapy several month trial ineffective , albeit less toxic , ET . To try predict benefit resistance ET , index ( CTC-ETI ) create take account number CTC ( prognostic ) well phenotype CTC , base hypothesis relative level ER Bcl-2 ( high=benefit ) HER2 Ki67 ( high=resistance ) predictive ET responsiveness resistance . Although preliminary data demonstrate ability detect , enumerate , characterize CTC utilize CellSearch® System , purpose current study establish proof principle 4 marker use generate CTC-ETI perform baseline patient enrol different center , baseline CTC-ETI predicts relative outcome patient ER positive MBC start new ET , monitor patient ET . Successful completion study set stage large , definitive study design demonstrate clinical utility `` refine '' CTC-ETI patient ER positive , HER2 negative MBC .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplastic Cells , Circulating</mesh_term>
	<criteria>Signed informed consent . Women 18 year old . Patients must estrogen receptor ( ER ) positive , HER2 negative metastatic breast cancer ( MBC ) least one nonirradiated distant site metastasis . ECOG performance status 02 . Patients must currently progressive metastatic disease accord RECIST v1.1 criterion , AND They progress least one previous line endocrine therapy ( ET ) metastatic disease ( currently progress fulvestrant ) , OR ; They show evidence disease progression within 12 month end adjuvant ET . Patient start new line ET metastatic disease Patient willing able undergo standard care image study ( imaging/staging modality use evaluation ) , anticipate perform prior initiation therapy subsequently every 3 month . Patient agree collection test blood willing able provide approximately 40mL blood draw ( ) : Baseline ( prior initiation new ET ) , ; Subsequently 1 , 2 , 3 12 month initiation therapy , and/or ; Time disease progression . Patients local regional recurrence brain metastasis . Patients progress current fulvestrant therapy ( patient fulvestrant therapy past subsequently treat therapy start fulvestrant next line ET eligible study ) . Patients take unapproved ( i.e . cleared/approved FDA ) antineoplastic therapy concurrently eligible ( exception : ET everolimus acceptable ) . Patients concomitant malignancy previous malignancy within last 5 year , exception adequately treat basal squamous cell carcinoma skin carcinoma situ cervix . Unable provide inform consent high risk patient may comply protocol requirement ( i.e . due health and/or participation research study ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>circulate tumor cell</keyword>
	<keyword>CTC</keyword>
	<keyword>metastatic breast cancer</keyword>
	<keyword>endocrine therapy</keyword>
	<keyword>hormone therapy</keyword>
</DOC>